Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis

Asma Kazemi,1 Vida Mohammadi,2 Sahar Keshtkar Aghababae,3 Mahdieh Golzarand,4 Cain CT Clark,5 and Siavash Babajafari1
1Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran; 2Department of Nutrition, Sepidan Bagherolooom Health Higher Education College, Shiraz University of Medical Sciences, Shiraz, Iran; 3Department of Nursing, College of Medical Sciences, Qazvin Branch, Islamic Azad University, Qazvin, Iran; 4Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; and 5Centre for Intelligent Healthcare, Coventry University, Coventry, United Kingdom

ABSTRACT
This systematic review was conducted to summarize and clarify the evidence on the association between 25-hydroxyvitamin-D [25(OH)D] concentrations and coronavirus disease 2019 (COVID-19) risk and outcomes. PubMed, Scopus, and Web of Science databases and Google Scholar were searched up to 26 November 2020. All retrospective and prospective cohort, cross-sectional, case-control, and randomized controlled trial studies that investigated the relation between 25(OH)D and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 severity were included. Thirty-nine studies were included in the current systematic review. In studies that were adjusted (OR: 1.77; 95% CI: 1.24, 2.53; \(I^2: 44.2\%\)) and nonadjusted for confounders (OR: 1.75; 95% CI: 1.44, 2.13; \(I^2: 33.0\%\)) there was a higher risk of SARS-CoV-2 infection in the vitamin D deficiency (VDD) group. Fifteen studies evaluated associations between VDD and composite severity. In the studies that were adjusted (OR: 2.57; 95% CI: 1.65, 4.01; \(I^2: 90.8\%\)) and nonadjusted for confounders (OR: 10.61; 95% CI: 2.07, 54.23; \(I^2: 0.0\%\)) there was a higher severity in the VDD group. Analysis of studies with crude OR (OR: 2.62; 95% CI: 1.13, 6.05; \(I^2: 47.9\%\)), and adjusted studies that used the Cox survival method (HR: 7.67; 95% CI: 3.92, 15.03; \(I^2: 0.0\%\)) indicated a significant association of VDD with mortality, while in adjusted studies that used logistic regression, no relation was observed (OR: 1.05; 95% CI: 0.63, 1.75; \(I^2: 76.6\%\)). The results of studies that examined relations between VDD and intensive care unit (ICU) admission, pulmonary complications, hospitalization, and inflammation were inconsistent. In conclusion, although studies were heterogeneous in methodological and statistical approach, most of them indicated a significant relation between 25(OH)D and SARS-CoV-2 infection, COVID-19 composite severity, and mortality. With regard to infection, caution should be taken in interpreting the results, due to inherent study limitations. For ICU admission, inflammation, hospitalization, and pulmonary involvement, the evidence is currently inconsistent and insufficient. Adv Nutr 2021;12:1636–1658.

Keywords: COVID-19, vitamin D, severity, infection, SARS-CoV-2

Introduction
Vitamin D deficiency (VDD) and insufficiency in adults and children, as a global problem, is associated with several disorders, including metabolic disorders, autoimmune diseases, cardiovascular disease, diabetes, and infections, and has been widely considered by researchers and clinicians (1). In particular, several studies have investigated the link between the risk of respiratory tract infections and VDD (2). For instance, Mamani et al. (3) reported an association between incidence of community-acquired pneumonia and low serum concentrations of 25-hydroxyvitamin D [25(OH)D], and adverse outcomes were observed in acute respiratory distress syndrome (ARDS) patients with VDD (4).

Vitamin D is a fat-soluble vitamin that plays an important role in several physiological processes, such as bone metabolism, calcium and phosphorus absorption, and immune system function (5). It may reduce the risk of microbial infections through stimulating innate cellular immunity, inhibiting the cytokine storm, decreasing proinflammatory cytokine production, and modulating the adaptive immune response (6). Vitamin D3 and vitamin D2 are 2 primary metabolites of vitamin D (7). Unstable 7-dehydrocholesterol in the skin is transformed to pre-vitamin D3 and stable vitamin D3, respectively, when exposed to UV-B radiation (8). Vitamin D3, or cholecalciferol, can also be found in foods, such as dairy products, eggs, and fish (9). Vitamin D3 is subsequently converted to 25-hydroxyvitamin D3...
(25(OH)D)₃ through 25-hydroxylase enzyme activity during the hydroxylation process in the liver. The 25(OH)D₃ form then transfers to the kidney and converts to 1α,25-dihydroxyvitamin D₃ via 1α-hydroxylase, otherwise known as calcitriol, the active form of vitamin D (8, 10).

Currently, the global community is involved in a novel pandemic named coronavirus disease 19 (COVID-19), a respiratory tract infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (11). The WHO reported the total global cases of SARS-CoV-2 infection and death as >61.8 and 1.4 million, respectively (weekly epidemiological update, 1 December 2020) (12). This novel coronavirus (SARS-CoV-2), like the other viruses of the β-coronavirus family, is extremely contagious, and COVID-19 symptoms vary from initially mild symptoms such as dry cough, fever, fatigue, and gastrointestinal symptoms, to severe situations requiring admission to an intensive care unit (ICU) or death in severe cases (13, 14). In some cases, inflammation can increase following both local and systemic immune responses generated by this virus and an increased number of leukocyte and concentrations of plasma proinflammatory cytokines have been reported in patients infected with SARS-CoV-2 (15).

Several studies have investigated the association of 25(OH)D₃ concentrations and supplementation with the risk and severity of respiratory virus infections (16, 17). Indeed, Martineau et al. (18) conducted a meta-analysis that included 25 placebo-controlled clinical trials (total of 10,933 people) and concluded that vitamin D supplementation reduces the risk of acute respiratory infections, especially in people with the lowest 25(OH)D₃ concentrations.

Recently, a growing body of evidence has emerged regarding potential factors affecting the incidence and severity of COVID-19 (19–21). Recent reports highlight that certain factors may be effective in controlling this pandemic or reducing the damage caused by it. Indeed, based on the global prevalence of VDD (22), it has attracted considerable attention as a potential factor associated with the risk or severity of COVID-19, and several studies have reported on this possible association (6, 23–25). However, results currently preclude a clear consensus. Thus, we conducted this systematic review to summarize and clarify the evidence on the association between 25(OH)D concentrations and COVID-19 risk and outcomes.

Methods
The protocol of this study has been registered in PROSPERO International Prospective Register of Systematic Reviews (www.crd.york.ac.uk/prospero/index.asp, identifier CRD42020203903). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used in developing and conducting this systematic review (26).

Search strategy and study selection
PubMed, Scopus, and Web of Science databases and the first 500 Google Scholar search results were searched up to 26 November 2020, with no restriction in language. Reference lists of included studies and relevant review articles were also scanned for additional relevant studies. The following search strategy was used for our search: (Coronavirus or COVID-19 or SARS-CoV-2) AND (vitamin D or 25-OH-D or cholecalciferol or 25-hydroxycholecalciferol or calcitriol or 25-hydroxyvitamin D or hydroxycholecalciferols or 25-hydroxyvitamin D₃).

Two reviewers independently assessed the eligibility of studies. Studies that met the following criteria were included: 1) study design as retrospective, prospective, or cross-sectional, or case-control studies reporting serum/plasma concentrations of 25(OH)D; 2) participants as patients diagnosed with COVID-19 with no restriction on age; 3) exposure/intervention as serum/plasma concentrations of vitamin D either reported as a continuous or categorical variable (deficiency vs. sufficiency); and 4) outcome as SARS-CoV-2 infection or COVID-19 severity, with severity defined as at least 1 of the following outcomes—ARDS and/or mechanical ventilation, ICU admission, length of hospitalization, and death. The exclusion criteria were as follows: 1) case reports, abstracts, and summaries of discussion; 2) insufficient data on vitamin D measurement or COVID-19 outcomes; 3) preprint studies without peer review; and 4) studies that were not individual based (compared countries or regions).

Data extraction and quality assessment
The following data were extracted independently by 2 reviewers: first author, study design, start and completion date, geographical location, age and gender composition of patients, objective of the study [if the aim of the study was to assess association of 25(OH)D status with risk of SARS-CoV-2 infection or to assess the association with severity of disease], definition of VDD, time of serum 25(OH)D measurement, prevalence of VDD and insufficiency, definition of disease severity, the number of events and nonevents in the case and control groups, relative risk and 95% CIs for SARS-CoV-2 infection and disease severity, and adjustment factors.

Quality assessment of observational studies was assessed using the Newcastle–Ottawa Scale, which included 3 items: selection, comparability, and outcome (27). Studies with a score of ≥7 were defined as high quality. The Cochrane risk-of-bias tool was used to evaluate quality assessment
Google Scholar and other sources. This tool included selection bias, performance and detection bias, attrition bias, reporting bias, and the other biases (28).

Statistical analysis
Wherever it was probable, we pooled data and conducted meta-analysis (SARS-CoV-2 infection, disease severity, ICU admission, and mortality). We used ORs to estimate the association between VDD and SARS-CoV-2 infection and COVID-19 severity. ORs with 95% CIs were obtained using a random-effects model. In studies that did not report relative risk, the OR was calculated by the number of events and nonevents in the case and control groups; these studies together with studies with crude ORs were analyzed separately from the studies that reported adjusted relative risk. To compare concentrations of 25(OH)D3 between groups, we used the weighted mean difference (WMD) and its 95% CI. Heterogeneity was evaluated using Cochran’s Q test, deriving its magnitude from the I². If at least 10 studies were available, we explored potential small-study effects, such as publication bias, using visual examination of the funnel plot and Egger’s test (29). All analyses were conducted using Stata version 13 software (StataCorp).

Results
Characteristics of the study population
As described in Figure 1, 1518 records were obtained by the literature search. Of these, 57 articles met the inclusion criteria; however, 3 studies were excluded because they used old 25(OH)D data, and 15 papers were preprints (Supplemental Table 1). Finally, 39 studies were included, with different geographical locations and ethnic backgrounds, including Europe (n = 17 studies), North America (United States) (n = 2), South America (n = 2), West Asia (n = 9), South Asia (n = 4), East Asia (n = 4), and Africa (n = 1). Ten studies were of a case-control design, 19 cross-sectional, 2 retrospective cohorts, 2 randomized controlled trials (RCTs), 2 quasi-experimental design, and 4 studies were only descriptive. All studies were conducted in adults, except for 1 study in children and 1 study in pregnant women. All studies,
except for 2, included both male and female participants; in 1 study, participants were only male (30), and in another, only females were included (31). Nine studies were not included in the analysis because 4 of them were only descriptive [only reported concentration of 25(OH)D in patients; Supplemental Table 2] (31–34), 1 study was in children (35), and 4 were different in design from other studies [they assessed the effect of 25(OH)D3 supplementation instead of 25(OH)D measurement] (14, 36–38).

Twenty-one studies examined the association of 25(OH)D concentrations with the severity; 14 studies with SARS-CoV-2 infection, whereas 10 of them assessed severity as a secondary outcome. Characteristics of studies that examined the association of vitamin D with SARS-CoV-2 infection are summarized in Table 1, and those examining COVID-19 severity are summarized in Table 2.

### Association of 25(OH)D status with SARS-CoV-2 infection

Nine studies evaluated the relation between VDD and SARS-CoV-2 infection. Studies that were adjusted (n = 3) (39–41) (OR: 1.77; 95% CI: 1.24, 2.53; I2: 44.2%; Figure 2A) and nonadjusted for confounders (n = 5) (42–45, 46) (OR: 1.75; 95% CI: 1.44, 2.13; I2: 33%; Figure 2B) indicated higher risk of infection in the VDD group (Figure 2). The Blanch-Rubió et al. (37) study was not included in analysis, because 4 of them were only descriptive [only reported concentration of 25(OH)D in patients; Supplemental Table 2] (31–34), 1 study was in children (35), and 4 were different in design from other studies (they assessed the effect of 25(OH)D3 supplementation instead of 25(OH)D measurement) (14, 36–38).

Twelve studies compared 25(OH)D concentration between COVID-19 patients and healthy subjects. The pooled analysis of 10 studies (41–49) revealed a lower concentration of 25(OH)D in cases compared with controls (WMD = −7.0 ng/mL; 95% CI: −9.49, −4.50; I2: 92.4%; cases, n = 1899; controls, n = 11,122; Supplemental Figure 1). Subgroup analysis indicated a greater difference in the studies that measured 25(OH)D after a SARS-CoV-2 test (WMD = −10.28 ng/mL; 95% CI: −14.41, −6.16; I2: 90.1%; n = 6 studies) compared with studies that used 25(OH)D data collected before a SARS-CoV-2 test (WMD = −3.0 ng/mL; 95% CI: −5.15, −0.86, I2: 80.3%; n = 4 studies). Two studies were not included in the analysis (35, 50); both studies indicated that 25(OH)D concentrations were significantly lower in cases compared with controls. In 1 study, the participants were children (35); the other study only reported that COVID-19 patients had a significantly lower 25(OH)D concentration compared with healthy counterparts; however, the mean ± SD values of 25(OH)D were not provided (50). Results of studies are summarized in Supplemental Table 3.

### Association of vitamin D status with COVID-19 severity

Twenty-one studies assessed the association of VDD with severity (composite severity or 1 feature of severity) as a primary outcome, and 10 studies as a secondary outcome.

### Composite severity

Fifteen studies evaluated the association between VDD and composite severity. Studies that were adjusted (38, 41, 44, 46, 51, 52) (OR: 2.57; 95% CI: 1.65, 4.01; I2 = 0.0%; Figure 3A) and nonadjusted for confounders (42, 45, 53–55) (OR: 10.61; 95% CI: 2.07, 54.23; I2 = 90.8%; Figure 3B) revealed a higher severity in the VDD group. Four studies were not included in the analysis; one of these studies was conducted in children and found a negative correlation between fever symptom and 25(OH)D concentration (P = 0.02), while no significant correlations were found between other clinical parameters and 25(OH)D concentration (35). The other study had a quasi-experimental design and indicated that vitamin D3 supplementation was inversely associated with Ordinal Scale for Clinical Improvement (OSCI) score for COVID-19 (β = −3.84; 95% CI: −6.07, −1.62; P = 0.001) (56). The third study, which assessed vitamin D supplementation in patients with a past history of COVID-19, found that it reduces the risk of exacerbation and worsening of the disease (OR: 0.29; 95% CI: 0.10, 0.083; P = 0.02) (57). The last study did not provide sufficient data, and only reported that VDD was significantly associated with severity; however, no data were available to indicate this (58). Results of studies have been summarized in Supplemental Table 4.

### ICU admission or stay

Four studies examined the relation between VDD and ICU admission or stay duration. Pooled analysis of 3 studies (38, 49, 59) with unadjusted ORs indicated no significant relation between VDD and ICU admission (OR: 1.17; 95% CI: 0.67, 2.03; I2 = 69.3%), while an RCT that was not pooled with these studies revealed a lower risk of ICU admission in the intervention group compared with the control group (OR: 0.03; 95% CI: 0.003, 0.25; P = < 0.001) (36). Carpagnano et al. (59) verified the association of VDD with ICU stay, highlighting that 10 patients with severe VDD had a median ICU stay of 8 d with the interquartile range (IQR) of 6 to 11.25., while 32 patients without VDD had a median stay of 12.5 d (IQR: 25.8, IQR: 25.0) (Supplemental Table 5).

### Pulmonary complications

Eight studies investigated the association of VDD with one of the pulmonary complication indicators. In Abrishami et al. (60), an increase in 25(OH)D concentrations yielded a reduction in the development of severe lung involvement (OR: 0.96; 95% CI: 0.93, 0.98; P = 0.04). Pizzini et al. (61) found no significant difference between 25(OH)D concentrations in patients with or without computed tomographic (CT) abnormalities (22 vs. 21.6 ng/mL; P = 0.83). Three studies assessed the relation between 25(OH)D concentration and progression to ARDS. In a prospective study in 33 hospitalized patients, the patients who progressed to ARDS had a lower serum 25(OH)D concentration on presentation to the hospital compared with non-ARDS patients [mean (SD): 10.8 (4.8) ng/mL in ARDS and 16.4 (7.6) ng/mL in non-ARDS patients; P = 0.03] (30), while there was no difference
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Definition of VitD deficiency | Time of VitD ascertainment | Objective/study question | Adjusting factors |
|-------------------|------------|------------------|--------|----------------|-------------|-----------------------------|--------------------------|----------------------|------------------|
| Bahat (31)        | April and June, 2020 | tertiary referral hospital, Turkey | Descriptive | 44 SARS-CoV-2-positive (+) pregnant women who were hospitalized, >8 wk of gestation | Mean age: 28.57; female: 100% | Serum 25(OH)D <20 ng/mL | On the day of admission | To measure serum 25(OH)D concentration in SARS-CoV-2+ pregnant women | — |
| Baktash (47)      | March 1 and April, 2020 | General hospital in the UK | Prospective cohort | 105 elderly (> 65 y) participants, 70 SARS-CoV-2+, 35 SARS-CoV-2 negative (−) | Mean age: 81.28; patients: 60% male; healthy: 40% | Serum 25(OH)D ≤12 ng/mL | Concurrent with SARS-CoV-2 test | Relation between VDD and SARS-CoV-2 infection | No adjustment for confounders; another limitation is vitamin D intake after the acute phase of illness Sex, age, comorbidities, treatment, and drugs |
| Blanch-Rubió (37) | March 1 to May 3, 2020 | Rheumatology service of hospital, Spain Switzerland | Cross-sectional | 2102 patients with noninflammatory rheumatic conditions | Mean age: 6664; 80.5% female | — | — | Effect of vitamin D intake on COVID-19 incidence | Sex, age, comorbidities, treatment, and drugs |
| D’Avolio (48)     | March 1 to April 14, 2020 | Retrospective cohort | Retrospective cohort | 27 SARS-CoV-2+, 80 SARS-CoV-2− | Median age: 73, IQR (63 to 81); male: 54.2% | — | — | The vitamin D analysis was required to be conducted within 7 wk of the SARS-CoV-2 PCR result | Describing the 25(OH)D plasma concentrations in a cohort of patients from Switzerland |
| De Smet (42)      | March 16 to April 16, 2020 | General hospital in Belgium | Retrospective observational study | 186 SARS-CoV-2+ hospitalized patients and 2717 diseased controls | Patients: median age, (IQR): 69 (52–80); male: 58.6%; controls: 68 (49–82); male: 36.8% | Serum 25(OH)D <20 ng/mL | Measured after SARS-CoV-2 test | Are lower 25(OH)D concentrations correlated with COVID-19? | — |
| Ferrari (43)      | February to April, 2020 | The San Raffaele Hospital, Milan, Italy | Retrospective cohort | 128 SARS-CoV-2+, 219 SARS-CoV-2− | Patients: 64.8% males; male age: 62.7; female age: 69.3; healthy: 48.85% males; male age: 62.8; female age: 54.3 | Serum 25(OH)D ≤30 ng/mL | The average time interval between SARS-CoV-2 test and their corresponding 25(OH)D measurements for the positive group was 33.9 and for the negative group was 33.33 d | — | — |

(Continued)
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Definition of VitD deficiency | Time of VitD ascertainment | Objective/study question | Adjusting factors |
|-------------------|------------|------------------|--------|---------------|-------------|--------------------------------|----------------------------|--------------------------|-------------------|
| Hernández (44) | March 10 to March 31, 2020 | University Hospital, Spain | Retrospective case-control study | 216 SARS-CoV-2+ and 197 population-based controls; in COVID-19 patients: number of VDD: 35; number of non-VDD: 162 | Cases: age, median (IQR): 61.0 (47.5–70.0); controls: 61.0 (56.0–66.0); male: 62.4% in both groups | Serum 25(OH)D <20 ng/mL | At admission | To assess serum 25(OH)D concentrations in hospitalized patients with COVID-19 and to analyze the possible influence of vitamin D status on disease severity | — |
| Im (45) | February to June, 2020 | Inha University Hospital, South Korea | Case-control | 50 patients with SARS-CoV-2+ and 150 controls | Mean age: 57.5 in case and 52.2 in control groups; male: 58% | Serum 25(OH)D <20 ng/mL | Within 7 d of admission | Prevalence of VDD among COVID-19 patients, comparing vitamin D status between COVID-19 patients and healthy individuals | Control group was matched for age and sex with the COVID-19 group |
| Kerget (50) | March 24, to May 15, 2020 | University Hospital in Turkey | Case-control | 88 SARS-CoV-2+, 20 SARS-CoV-2– | Mean age: cases: 49.1; male: 60%; controls: 35.2; male: 40% | — | Fifth day of admission to hospital | To determine the relation of serum vitamin D concentration between patients and healthy controls | — |
| Luo (46) | February 27 to March 21, 2020 | Hospital in China | Cross-sectional | 335 COVID-19 patients, age- and sex-matched population of 560 individuals | Patients: median (IQR) age: 56 (43–64); male: 44.2%; controls: age: 55 (49–60.0); male: 45.9% | Serum 25(OH)D <30 ng/mL | In control, serum 25(OH)D concentrations were measured during the same period from 2018–2019; in patients, serum 25(OH)D concentrations were measured on admission | To investigate whether VDD is associated with COVID-19 incidence | Age, sex, comorbidities, smoking status, and BMI |
| Mardani (49) | March, 2020 | A general clinic, Iran | Case-control | 63 SARS-CoV-2+, 60 SARS-CoV-2– | Median age of 39; male: 52% | Deficient [25(OH)D <10 ng/mL] or insufficient [25(OH)D: 10–30 ng/mL] | At baseline of the study | Relation between VDD and SARS-CoV-2 infection | Not adjusted |

(Continued)
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Definition of VitD deficiency | Time of VitD ascertainment | Objective/study question | Adjusting factors |
|-------------------|------------|-----------------|--------|----------------|--------------|----------------------------|---------------------------|------------------------|------------------|
| Meltzer (39)      | March 3 to April 10, 2020 | Academic hospital in USA | Retrospective cohort study | 63 SARS-CoV-2+; 365 SARS-CoV-2– | Mean age: 45.7; male: 25.2% | VDD was defined by the most recent 25(OH)D <20 ng/mL or 1,25(OH)D < 18 pg/mL | Within 1 y before SARS-CoV-2 test (subjects received treatment in this duration were excluded) | Is VDD associated with positive test for SARS-CoV-2? | Demographic and comorbidity |
| Merzon (40)       | February 1 to March 30, 2020 | Health Services in Israel | Retrospective cohort study | 782 SARS-CoV-2+; 7025 SARS-CoV-2– | SARS-CoV-2+: mean age: 35.6; male: 49.23%; SARS-CoV-2–: mean age: 47.4; male: 40.6% | "Suboptimal" or "low": plasma 25(OH)D < 30 ng/mL | At least 1 previous blood test for plasma 25(OH)D concentration | Is VDD risk factor for SARS-CoV-2 infection? | Demographic variables, psychiatric and somatic disorders |
| Sun (34)          | February to February, 2020 | Hospital University in Wuhan, China | Descriptive | 241 patients with confirmed COVID-19 | Median age: 65 (IQR: 55–72); male: 46.4% | — | — | — | — |
| Ye (41)           | February to March, 2020 | A Hospital in China | Case-control | 62 SARS-CoV-2+; 80 healthy controls | Controls: median age (IQR): 42 (31–52); male: 40%; patients: age: 43 (32–59); male: 37% | 25(OH)D < 20 ng/mL | At admission | To examine the relation between serum 25(OH)D concentration and SARS-CoV-2 infection | Demographics and comorbidities |
| Yılmaz (35)       | March to May, 2020 | University Hospital in Turkey | Case-control | 85 children (40 SARS-CoV-2+ and hospitalized, 45 healthy children in control group) | COVID-19 patients: 101.76 mo; male: 47.5% controls: 75.68 mo; male: 60% | 25(OH)D < 12 ng/mL | From retrospective file records | Is VDD a risk factor for COVID-19 in children? | None |

1 COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction; ref, reference; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VDD, vitamin D deficiency; VitD, vitamin D; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)D, 1,25-hydroxyvitamin D.
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Objective/study question | Severity definition/vitamin deficiency definition | Time of VitD ascertainment | Adjusting factors |
|-------------------|------------|------------------|--------|----------------|-------------|--------------------------|-----------------------------------------------|--------------------------|------------------|
| Abrishami (60)    | February to April, 2020 | Academic hospital in Iran | Retrospective study | 73 SARS-CoV-2–positive (+) patients | Mean age: 55.18; male: 46.4% | To evaluate the prognostic role of serum 25(OH)D$_3$ on the extent of lung involvement and final outcome in patients with COVID-19 | Lung involvement and mortality; serum 25(OH)D <25 ng/mL | At admission | For mortality, multivariate linear regression analysis adjusted for potential confounders including sex, age, and comorbidity |
| Anjum (62)        | March to June, 2020 | A hospital in Pakistan | Prospective | 140 SARS-CoV-2+ patients | Mean age: 42.46; age range: 15–75; male: 58.57% | To determine the association between severe VDD and mortality in patients with COVID-19 | Severity was defined as mortality; severe VDD was defined as 25(OH)D <10 ng/mL | At admission | — |
| Annweiler (56)    | March to April, 2020 | Nursing home in France | Quasi-experimental study with mean follow-up of 36 d | 66 frail elderly nursing-home residents: intervention, n = 57; comparator, n = 9 | Experiment: mean age: 87.7; male: 21%; Comparator: mean age: 87.4; male: 33% | To evaluate COVID-19 severity and the use of COVID-19 drugs; the primary and secondary outcomes were COVID-19 mortality and OSCI score in acute phase | OSCI score | The intervention group received VitD3 (single dose of 80,000 IU every 2–3 mo) during COVID-19 or in the preceding month; the comparator group corresponded to all other participants | Age, gender, drugs, functional abilities, albuminuria |
| Annweiler (51)    | March to May, 2020 | One geriatric acute care unit dedicated to COVID-19 patients in France | Quasi-experimental study | Group 1 (n = 29), group 2 (n = 16), group 3 (n = 32) | Mean age: 88; male: 51% | 14-day mortality and highest (worst) score on the OSCI measured during COVID-19 acute phase | To determine whether vitamin D3 supplementation taken either regularly over the preceding year or after the diagnosis of COVID-19 was | Group 1 (n = 29): supplemented regularly with VitD over the preceding year; Group 2 (n = 16): supplemented with VitD after | Potential confounders were age, gender, functional abilities, undernutrition, chronic |

(Continued)
| First author (ref) | Study date | Country, setting | Design                     | Sample size, n | Age (y); sex | Objective/study question                                                                 | Severity definition/vitamin deficiency definition                                                                 | Time of VitD ascertainment | Adjusting factors                                                                 |
|-------------------|------------|------------------|----------------------------|----------------|-------------|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------------------------|-------------------------------------------------------------------------------------|
| Arvinte (63)      | May, 2020  | ICU of medical center in Colorado, USA | Cross-sectional, descriptive | 21 critically ill COVID-19 patients hospitalized; 11 survived, 10 died | Median age 61; age range: 20–94; male: 71.4% | To measure serum 25(OH)D$_{2,3}$ in patients with critical COVID-19 illness and to assess if VDD correlated with other illness risk factors | Effective in improving survival among hospitalized frail elderly COVID-19 patients; severe COVID-19 defined as an OSCI score $\geq$ 5 Severity was defined as mortality | At ICU admission          | —                                                                                  |
| Baktash (47)      | March to April, 2020 | General hospital in the UK | Prospective cohort study | 70 elderly SARS-CoV-2+ individuals (aged $\geq$65 y); VDD patients: ($n = 39$); non-VDD patients: ($n = 31$) | Mean age: 81.28; Male: 60% in COVID-19 patients and 40% in non–COVID-19 patients | Vitamin D status and outcomes for hospitalized older patients with COVID-19 | Noninvasive ventilation and high-dependency unit; clinical markers of disease severity; 25(OH)D $\leq$ 12 ng/mL | Concurrent with SARS-CoV-2 test | Not adjusted for confounders; another limitation is the supplementation of VitD after the acute phase of illness |
| Bagheri (57)       | March to May 2020 | University hospital in Iran | Cross-sectional | 103 outpatients and 28 hospitalized patients | Mean age: 43.74 in outpatients and 58.77 in inpatients | The vitamin D supplementation pattern in past history of patients with COVID-19 in a cross-sectional inquiry | Severity was considered as hospitalization | Supplemented or not supplemented with vitamin D | Adjusted for the factors affecting the severity of this disease |
| Carpagnano (64)    | March 11 to April 30, 2020 | Italy, hospital polyclinic | Retrospective, observational study | 42 patients with ARF due to COVID-19, treated in respiratory intermediate care unit, and no need of intubation or invasive ventilation | Mean age: 65; male: 71% | Assessing any correlations with disease severity and prognosis | Transfer to ICU, death; vitamin D insufficiency, moderate deficiency, and severe deficiency were defined as 25(OH)D concentrations of 20–29, 10–19, and $<$10 ng/mL, respectively | Measured after SARS-CoV-2 test | —                                                                                  |
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Objective/study question | Severity definition/vitamin D deficiency definition | Time of VitD ascertainment | Adjusting factors |
|-------------------|------------|------------------|--------|----------------|-------------|--------------------------|-----------------------------------------------|---------------------------|------------------|
| Entrenas Castillo (36) | May, 2020 | University hospital, Spain | RCT | 76 patients hospitalized with SARS-CoV-2 infection (50 in the intervention and 26 in the control) | Mean age: 53; male: 59% | Effect of calcifediol treatment on ICU admission and mortality rate among patients hospitalized for COVID-19 | Admission to ICU (0.53 mg VitD at admission, 0.26 mg at day 3 and 7, and then weekly until discharge or ICU admission) | Not measured | Adjusted for variables that were different between groups at baseline (HTN, DM); MLR analysis for probability of the ICU admission |
| Cereda (65) | March to April, 2020 | Italian tertiary referral hospital | Single-center cohort study | 129 COVID-19 patients: VDD group, n = 99; non-VDD, n = 30 | Median age: 77 (IQR, 65.0, 85.0); male: 54.3% | To determine the prevalence of VDD in COVID-19 patients and explore its association with clinical outcomes of disease severity | Clinical outcomes (severe pneumonia, admission to ICU and in-hospital mortality) and biochemical markers of disease severity 25(OH)D < 20 ng/mL | Within 48 h since hospital admission | Age, sex, CRP, IHD, and severe pneumonia |
| De Smet (42) | March 1 to April 7, 2020 | Belgium, general hospital | Retrospective observational study | 186 hospitalized SARS-CoV-2–infected patients | Age 68.5; male: 58.6% | Are lower 25(OH)D concentrations correlated with COVID-19 severity? | Patients were classified based on the radiological lesion as early stage 1 (ground-glass opacities), progressive stage 2 (crazy paving pattern), or peak stage 3 (consolidation). 25(OH)D < 20 ng/mL | Measured after SARS-CoV-2 test | None |
| Haraj (33) | April 17 to May 26, 2020 | Endocrinology service in Morocco | Descriptive observational study | 41 patients admitted to the endocrinology service for additional care after a stay in ICU | Mean age: 55 < 45 years (26.8%), 45–70 years (48.8%), > 70 (24.4%); 51.2% male | To assess the vitamin D status of patients with COVID-19 after a stay in intensive care | — | At the beginning of the study | — |
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Objective/study question | Severity definition/vitamin deficiency definition | Time of VitD ascertainment | Adjusting factors |
|-------------------|------------|------------------|--------|----------------|-------------|-------------------------|-----------------------------------------------|-----------------------------|-----------------|
| Faul (30)         | During March, 2020 | Ireland, Connolly Hospital Blanchardstown | Cohort | 33 hospitalized for COVID-19-related pneumonia; cases: patients progressed to ARDS (n = 12); controls: those who did not progress to ARDS (n = 21) | Mean age: 60; male: 100% | Does low 25(OH)D contribute to severe disease and progression to ARDS in some patients infected with SARS-CoV-2? | Progression to ARDS, require intubation and mechanical ventilation, death | Measured after admission to hospital | — |
| Ferrari (43)      | February 20 to April 7, 2020 | San Raffaele Hospital, Milan, Italy | Retrospective cohort | 128 SARS-CoV-2+ patients: severe disease (n = 16), nonsevere (n = 112) | Mean age: 62.7; male: 64.8% | Association between COVID-19 severity and VitD concentrations | Severity classification was not explained; 25(OH)D <30 ng/mL | — | — |
| Gonçalves (32)    | March to April, 2020 | ICU in Brazil | Descriptive cross-sectional study | 176 elderly (aged ≥60 y) | Mean age: 72.9; male: 54% | Prevalence of VDD in elderly patients admitted to the ICU due to SARS-CoV-2 | — | In the first day of ICU admission | — |
| Hamza (58)        | March to April, 2020 | Medical college hospital in Pakistan | Descriptive cross-sectional study | 168 SARS-CoV-2+ patients | Age ranged from 30 to 80; mean age: 42.26; male: 56% | To determine the VDD in COVID-19 patients and its association with the severity and fatality of COVID-19 disease | The COVID-19 patients were categorized into asymptomatic and symptomatic; the symptomatic patients were categorized into mild, moderate, and severe disease according to questionnaire | At the beginning of the study | — |
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Objective/study question | Severity definition/vitamin deficiency definition | Time of VitD ascertainment | Adjusting factors |
|--------------------|------------|------------------|--------|----------------|-------------|--------------------------|-----------------------------------------------|-----------------------------|-----------------|
| Hernández (44)     | March 10 to March 31, 2020 | University hospital in Spain | Retrospective case-control study | 197 COVID-19 patients; cases were the patients with VDD (n = 35); control patients with non-VDD (n = 162) | Age, median (IQR): 61.0 (47.5–70.0) in cases, 61.0 (56.0–66.0) in controls; male: 62.4% | To assess serum 25(OH)D3 in hospitalized patients with COVID-19 and to analyze the possible influence of vitamin D status on disease severity | Admission to ICU, requirement for mechanical ventilation, or in-hospital mortality; 25(OH)D <20 ng/mL | At admission | Age, smoking, chronic disease, immunosuppression, BMI, serum-corrected calcium, GFR, and the month of vitamin D determination |
| Im (45)             | February to June, 2020 | University hospital, South Korea | Case-control | 50 patients with COVID-19, 32 with pneumonia and 18 without pneumonia | Median age: 57.5 in cases and 52.2 in controls; male: 58% | Association of 25(OH)D3 with disease severity (defined by pneumonia) | Progression to pneumonia includes cases with or without an oxygen supply, high-flow nasal cannula, mechanical ventilator, and ECMO/death was considered as severe; 25(OH)D3 ≤20 ng/dL | Within 7 d of admission | — |
| Jain (53)           | June 5 to July 20, 2020 | Tertiary COVID-19 care center in India | Prospective observational | Study included both asymptomatic COVID-19 patients (group A, n = 91) and severely ill patients requiring ICU admission (group B, n = 63) | 30–60 y: Group A: mean age: 42.34; male: 38.2%; Group B: mean age: 51.41; male: 66.66% | Analysis of vitamin D concentration among asymptomatic and critically ill COVID–19 patients and its correlation with inflammatory markers | Asymptomatic vs. ICU patients; 25(OH)D <20 ng/dL | At the beginning of the study | Not adjusted |
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Objective/study question | Severity definition/vitamin deficiency definition | Time of VitD ascertainment | Adjusting factors |
|-------------------|------------|-----------------|--------|----------------|-------------|--------------------------|------------------------------------------|--------------------------|------------------|
| Karahan (54)      | April 1 to May 20, 2020 | Training and research hospital, Turkey | Retrospective observational study | 149 COVID-19 patients; moderate (n = 47), severe–critical (n = 102) | Mean age: 63.5; age range: 24–90; male: 54.4% | To investigate the role of serum 25(OH)D concentration on COVID severity and related mortality | The severity of COVID was classified according to the Chinese Clinical Guideline for classification of COVID-19 severity⁶; 25(OH)D < 20 ng/dL | Data were retrieved from the hospital electronic database system | Confounding factors not mentioned |
| Šaronova (55)     | April 1 to May 15, 2020 | Hospital in Russia | Cross-sectional | 80 COVID-19 patients; severe: (n = 25), moderate: (n = 55) | All patients: Age range: 18–94; mean age: 53.2; male: 53.8%; Severe disease: mean age: 51.8; male: 48%; Moderate disease: mean age: 53.7; male: 56.4% | — | — | — |
| Kerget (50)       | March 24 to May 15, 2020 | Two hospitals in Turkey | Case-control | 88 COVID-19 patients; 20 patients developed MAS and 35 developed ARDS and 8 died | Mean age: MAS: 70.1; non-MAS: 43.4; ARDS: 67.9; non-ARDS: 38.3 | To determine the relation of serum 25(OH)D to clinical course and prognosis | Developing MAS and ARDS, and death | Fifth day of admission to hospital | — |
| Luo (46)          | February to March 2020 | Wuhan Tongji Hospital | Cross-sectional | 335 COVID-19 patients; 74 severe, 261 nonsevere | Severe: Median age: 62.5; IQR: 51.0–75.3 y; male: 58.1%; Nonsevere: Median age: 54; IQR: 40–62 y; male: 40.2% | To investigate whether VDD is associated with COVID-19 disease severity | Severity of COVID-19 was determined based on the level of respiratory involvement; based on Commission and State Administration of Traditional Chinese Medicine⁷; 25(OH)D < 30 ng/mL | For the control group, serum 25(OH)D data on the same period from 2018–2019 were used; for the COVID-19 patients, on admission to hospital | Age, sex, comorbidities, smoking status, and BMI |

(Continued)
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Objective/study question | Severity definition/vitamin deficiency definition | Time of VitD ascertainment | Adjusting factors |
|-------------------|------------|------------------|--------|----------------|-------------|--------------------------|-----------------------------------------------|---------------------------|------------------|
| Macaya (52)       | —          | Tertiary hospital in Madrid, Spain | Retrospective | 80 COVID-19 patients (nonsevere; \( n = 49 \); severe; \( n = 31 \)) | Nonsevere: Median age: 63; IQR (50–72); male: 29% Severe: Age: 75 (66–84); male: 21% Mean age was 58.7; age range: 20–90; male: 61.3% | The association of VDD with a composite of adverse clinical outcomes | Death, admission to the ICU, and/or need for higher oxygen flow than that provided by a nasal cannula; 25(OH)D <20 ng/mL | At admission or within the 3 previous months | Obesity, cardiac disease, and age |
| Maghbooli (38)    | Until May 1, 2020 | A hospital in Tehran | Cross-sectional | 235 COVID-19 patients mild–moderate severity: \( n = 64 \); severe–critical severity: \( n = 172 \) | To investigate the association between serum 25(OH)D and clinical outcomes, parameters of immune function and mortality Is VDD a risk factor for COVID-19 hospitalization? | CDC criteria were used for the disease severity and prognosis; 25(OH)D <30 ng/mL | At admission to the hospital | Age, sex, BMI, smoking, and history of a chronic medical disorder |
| Merzon (40)       | February to March, 2020 | Israel, Health Services | Retrospective cohort study | 782 SARS-CoV-2+ patients; mean age: 35.6; male: 49.23% SARS-CoV-2–negative (–): age: 47.4; male: 40.6% | Hospitalization was considered as the marker of severity; 25(OH)D <30 ng/mL | Severe COVID-19 was defined as admission to ICU and mortality; 25(OH)D <20 ng/mL | At least 1 previous blood test for plasma 25(OH)D concentration | Demographic variables, psychiatric and somatic disorders |
| Panagiotou (59)   | —          | UK, local clinical care pathway | Retrospective interim audit | 134 SARS-CoV-2+ patients, 42 admitted to ICU; deceased: 16 Mean age: 65.9; male: 48.7% | The prevalence of VDD among COVID-19 inpatients, and its associations with disease severity | Severe COVID-19 was categorized as admission to ICU and mortality; 25(OH)D <20 ng/mL | Measured after COVID-19 testing | Age, gender, comorbidities, and CRP concentrations for mortality |
| Pizzini (61)      | Began on April 29, 2020, ongoing | Several hospitals and care centers in Austria | Prospective multicenter observational study | 22 non-hospitalized (mild) and 87 hospitalized patients (moderate: 34; severe: 53); 38% with VDD Median age: 58; male: 60% | To investigate associations of vitamin D status to disease presentation Disease severity was categorized as mild for patients in outward treatment; moderate for patients in inward treatment; and severe for patients requiring oxygen supply, respiratory support, or ICU; 25(OH)D <12 ng/mL | The 25(OH)D concentration was measured 2 times: the first days of hospital admission and 8 wk after the diagnosis | — | — |

(Continued)
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Objective/study question | Severity definition/vitamin deficiency definition | Time of VitD ascertainment | Adjusting factors |
|-------------------|------------|-----------------|--------|----------------|-------------|--------------------------|-----------------------------------------------|--------------------------|------------------|
| Pérez (66)        | —          | Hospital Central Military Mexico | —      | 172 patients with COVID-19; cases: those who died (n = 35); controls: those who survived | Mean age: 51.44; male: 77.3% | Determine the association between 25(OH)D concentrations and mortality in hospitalized patients with COVID-19 | Mortality was considered as severe; 25(OH)D <20 ng/dL | —            | —                |
| Radujkovic (13)   | March to June, 2020 | Medical University hospital, Heidelberg, Germany | Cohort | 185 patients; patients with VDD (n = 41); non-VDD (n = 144); outpatients: 92; inpatients: 93 | Median age: 60, IQR (49–70); male: 51% | To explore possible associations of vitamin D status with disease severity and survival | Decision for inpatient vs. outpatient admission was based on spontaneous oxygen saturation, comorbidities, and the overall performance status; based on COVID-19 severity classifications, all inpatients had severe disease (defined as tachypnea, oxygen saturation <93% at rest, or ICU requirement); 25(OH)D <12 ng/mL | At the time of admission | Adjusted for age, gender, and comorbidities |
| Rastogi (14)      | —          | Tertiary care hospital in north India | RCT    | 40 Asymptomatic or mildly symptomatic SARS-CoV-2+ with VDD [25(OH)D <20 ng/mL] | Median age in the intervention group: 50.0, IQR (36–51); male: 37.5% Control: 47.5 (39.3 to 49.2); male: 58.3% | Effect of high-dose oral cholecalciferol supplementation on SARS-CoV-2 viral clearance | — | At the beginning of study | — |
| Ye (41)           | February to March, 2020 | Guangxi People’s Hospital, China | Case-control | 80 healthy controls and 62 patients diagnosed with COVID-19 | Median age in controls: 42, IQR (31–52); male: 40% Age in cases: 43 (32–59); male: 37% | To examine the relationship between serum 25(OH)D₃ concentration and COVID-19 severity, and its clinical case characteristics | Severe COVID-19 case was defined according to the guidelines of the National Health Commission of China⁵; 25(OH)D <20 ng/dL | At admission | Demographics and comorbidities |
| First author (ref) | Study date | Country, setting | Design | Sample size, n | Age (y); sex | Objective/study question | Severity definition/vitamin deficiency definition | Time of VitD ascertainment | Adjusting factors |
|-------------------|------------|-----------------|--------|----------------|-------------|--------------------------|--------------------------------------------------|--------------------------|-----------------|
| Yılmaz (35)       | March to May 2020 | Turkey, Dicle University Faculty of Medicine | Case-control | 85 children (40 patients who were diagnosed with COVID-19 and hospitalized, 45 healthy children in the control group) | COVID-19 patients: 101.76 ± 27.91 mo; male: 47.5%; Controls: 75.68 ± 27.34 mo; male: 60% | To determine the prevalence and clinical importance of VDD in children and adolescent patients who were hospitalized with the diagnosis of COVID-19 | Mild cases with upper respiratory tract infection with normal respiratory system examination. Moderate pneumonia with fever and cough but without symptoms of dyspnea and hypoxemia or cases with findings of COVID-19 on CT scan without any symptoms. Severe: fever and cough in the early period who develop dyspnea and central cyanosis. Critical: develop ARDS or RF rapidly. | From retrospective file records | None |

1 ARF, acute respiratory failure; ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; CT, computed tomography; DM, diabetes mellitus; ECMO, extracorporeal membrane oxygenation; FIO₂, fraction of inspired oxygen; GFR, glomerular filtration rate; HTN, hypertension; ICU, intensive care unit; IH, ischemic heart disease; MAS, macrophage activation syndrome; MLR, multivariate logistic regression (OSC); Ordinal Scale for Clinical Improvement; PaO₂, partial oxygen pressure; RCT, randomized controlled trial; ref, reference; RF, renal failure; SARs-Cov-2, severe acute respiratory syndrome coronavirus 2; SpO₂, oxygen saturation; VDD, vitamin D deficiency; VD, vitamin D; 25(OH)D, 25-hydroxyvitamin D; 25(OH)D₃, 25-hydroxyvitamin D₃; 1,25(OH)₂D, 1,25-hydroxyvitamin D. 

2 Chinese Clinical Guideline for classification of COVID-19 severity. Moderate: fever and pulmonary symptoms along with pneumonia on radiologic imaging. Severe: the presence of any of the following criteria: 1) respiratory distress (>30 breaths/min), 2) oxygen saturation ≤93% at rest, 3) PaO₂/FIO₂ < 300 mmHg or chest imaging shows obvious lesion progression >50% within 24–48 h. 

3 Commission and State Administration of Traditional Chinese Medicine: 1) mild: mild symptoms with no signs of pneumonia on imaging, 2) moderate: fever, respiratory symptoms with radiological evidence of pneumonia, 3) severe: i.e., meeting any of the following: respiratory distress, respiratory rate > 30 breaths/min, hypoxemia, SpO₂ ≤ 93% (at rest), or lung infiltrates of >50% within 24–48 h; and 4) critical (i.e., meeting any of the following criteria: respiratory failure requiring mechanical ventilation, shock, or multiple organ dysfunction requiring ICU monitoring and treatment). 

4 CDC criteria were used for the disease severity and prognosis, which includes mild–moderate (mild respiratory symptoms and fever on an average of 5–6 d after infection), severe disease (dyspnea, respiratory frequency ≥30 breaths/min, blood oxygen saturation ≤ 93%, and/or lung infiltrates >50% of the lung field within 24–48 h) and critical (respiratory failure, septic shock, and/or multiple organ dysfunction/failure). 

5 Per Guidelines of the National Health Commission of China severe cases met at least 1 of the following criteria: 1) respiratory rate > 30 breaths/min, 2) pulse oximeter SpO₂ ≤ 93% when breathing ambient air, 3) ratio of PaO₂ to FIO₂ ≤ 300 mmHg (1 mmHg = 0.133 kilopascal), and 4) lung imaging showing significant progression of > 50% within 24 to 48 h. Critical cases were defined as having at least 1 of the following: 1) respiratory failure (PaO₂ < 60 mmHg when breathing ambient air), 2) hemodynamic shock (persisting hypotension requiring vasopressors to maintain mean arterial pressure > 65 mmHg and serum lactate concentration > 2 mmol/L despite resuscitation), and 3) organ failure or admission to ICU.
between concentrations of 25(OH)D in ARDS [mean (SD): 16.8 (10.5) ng/mL] and non-ARDS [21.8 (15.8)] patients in Kerget et al. (50) \(P = 0.10\). Similarly, no significant association between VDD and ARDS was observed in the Maghbooli et al. (38) study (17.1% in VDD vs. 11.7% in non-VDD that progressed to ARDS; \(P = 0.33\)); moreover, bilateral lung involvement was observed in 33.3% in VDD versus 31.7% in non-VDD \(P = 0.86\) in this study. Three remaining studies evaluated the relation between VDD and risk of ventilation requirement. In a prospective study, VDD increased the risk of invasive mechanical ventilation and/or death (HR: 6.12; 95% CI: 2.79, 13.42; \(P < 0.001\)) (13). Consistently, another study indicated a significant relation between VDD and ventilation requirement (OR: 4.15; 95% CI: 1.05, 16.34; \(P = 0.042\)) (47), while one reported no relation (22.8% in VDD vs. 17.14% in non-VDD; \(P = 0.58\)) (44). Confounders were adjusted in the Radujkovic et al. (13) and Abrishami et al. (60) studies, while not adjusted in the Baktash et al. (47), Hernández et al. (44), Kerget et al. (50), Faul et al. (30), Maghbooli et al. (38), Pizzini et al. (61), and Im et al. (45) studies, respectively. Results of studies are summarized in Supplemental Table 6.

**Hospitalization**

Three studies investigated the relation between 25(OH)D and hospital admission and 2 with hospital stay. A significant association between VDD and risk of hospitalization was observed in Radujkovic et al. (13) (31% hospitalization in VDD vs. 69% in non-VDD, \(P = 0.004\)) and a marginally significant relation in Merzon et al. (40) (adjusted OR: 1.95; 95% CI: 0.98, 4.845; \(P = 0.06\)). The third study was a cross-sectional study that compared history of vitamin D3 supplement intake between inpatients and outpatients (57), where vitamin D3 intake was reported in 30% of outpatients versus 16.5% of hospitalized patients \(P = 0.001\).

Hernández et al. (44) found a significant relation between VDD and hospital stay [median (IQR) of 12.0 d (8.0–16.0) in patients with VDD vs. 8.0 d (6.0–14.0) in non-VDD patients; \(P = 0.01\)], while Luo et al. (46) failed to find a significant relation between serum 25(OH)D concentrations and length...
of hospital stay ($B = -0.03, P = 0.64$) (Supplemental Table 7).

Concentration of 25(OH)D between severe and less severe status of disease
Thirteen studies compared the serum concentration of 25(OH)D between patients with severe and nonsevere status of COVID-19 (either composite or 1 feature of severity). Analysis of 12 studies (13, 30, 41, 42, 43, 46, 50, 53–55, 59, 61), with 806 cases and 1024 controls, indicated that serum concentrations of 25(OH)D in patients with severe status of disease was lower (WMD = −7.17 ng/mL; 95% CI: −9.99, −4.34; $I^2 = 87.6\%$) compared with less-severe counterparts (Supplemental Figure 2). In all of the studies except for one (43), 25(OH)D was measured after SARS-CoV-2 testing. One study was not included in the analysis, since the sample size according to hospitalization was not reported. Indeed, in this retrospective study, mean concentrations of 25(OH)D were 18.38 ng/mL (95% CI: 16.79, 19.96) in hospitalized and 20.45 ng/mL (95% CI: 20.22, 20.68) in nonhospitalized individuals ($P < 0.001$) (40) (Supplemental Table 8).

Inflammatory markers
We assessed the association of VDD with C-reactive protein (CRP), IL-6, D-dimer, and ferritin in COVID-19 patients. Nine studies examined the association of at least 1 of these markers with VDD. In an RCT in 40 COVID-19 patients, cholecalciferol supplementation did not significantly reduce CRP and D-dimer (14). A retrospective study in 42 patients with acute respiratory failure due to COVID-19 (64) revealed no statistically significant differences in inflammation indices among the 4 vitamin D groups (normal, insufficiency, deficiency, severe deficiency). Another retrospective study in 197 COVID-19 patients revealed that only ferritin, but not CRP, IL-6, and D-dimer, was significantly higher in VDD compared with non-VDD (44). In a prospective multicenter observational study in 109 patients, the correlation between 25(OH)D concentrations at follow-up and CRP, IL-6, ferritin, and D-dimer was not significant. The same was true for 25(OH)D concentrations measured at disease onset and CRP ($r = 0.152, P = 0.45$), IL-6 ($r = 0.050, P = 0.80$), and ferritin ($r = 0.070, P = 0.73$). In contrast, D-dimer concentrations were moderately associated with 25(OH)D concentrations ($r = 0.437, P < 0.05$) (61). Karahan and Katkat (54) in their retrospective study in 149 COVID-19 patients found a significant negative relation between serum 25(OH)D concentration and CRP ($r = -0.253, P = 0.002$). Kerget et al. (50) found a significant negative correlation only with CRP ($r = -0.297, P = 0.01$), but not IL-6, ferritin, and D-dimer. In a prospective study in 70 elderly individuals, it was reported that the VDD group demonstrated higher peak CRP, lactate dehydrogenase (LDH), and ferritin concentrations (47). Maghbooli et al. (38) in a cross-sectional study in 235 patients indicated that a relative risk of CRP >40 mg/L (inpatient mortality serum concentrations) was significantly higher in VDD. In Radujkovic et al. (13), IL-6 concentration was significantly higher in VDD versus non-VDD [median (IQR): 70.5 pg/mL (32.0–326.3) vs. 29.7 pg/mL (14.3–59.9); $P = 0.01$]. Only Maghbooli et al. and Radujkovic et al. adjusted for confounders, whereas the other studies did not report any adjustment. Results of studies are listed in Supplemental Table 9.

Mortality
Among 15 studies that assessed the relation between mortality and VDD, 13 studies were included in the analysis. Pooled analysis of 4 adjusted studies that used the Cox survival method (13, 51, 56, 60) (HR: 7.67; 95% CI: 3.92, 15.03; $I^2 = 0\%$; Figure 4A) and 5 studies (44, 47, 53, 55, 62) with crude OR (OR: 2.62; 95% CI: 1.13, 6.05; $I^2 = 47.8\%$; Figure 4B) indicated a significant association of VDD with mortality, while in adjusted studies that used logistic regression (54, 59, 63), no relation was observed (OR: 1.05; 95% CI: 0.63, 1.75; $I^2 = 76.6\%$). Two studies were not included in the analysis since 1 study had an RCT design (36) and another one used different statistical methods (64). In the RCT, 2 deaths in the control group versus no deaths in the intervention group were observed (36). In the other study, which had a retrospective design, patients with serum 25(OH)D <10 ng/mL had a 50% probability of mortality, while those with 25(OH)D ≥10 ng/mL had a 5% mortality risk after 10 d of hospitalization ($P = 0.02$) (64).

Moreover, 6 studies compared serum concentrations of 25(OH)D between deceased patients and those who survived (50, 54, 55, 60, 63, 66); pooled analysis of studies indicated lower concentrations of 25(OH)D in patients who died compared with those who survived (WMD: −9.05 ng/mL; 95% CI: −13.86, −4.23; $I^2 = 87.8\%$; Supplemental Figure 3). Results of studies are summarized in Supplemental Table 10.

Publication bias and quality assessment
Assessment of publication bias was conducted for 25(OH)D concentration between SARS-CoV-2–positive and –negative subjects as well as between severe and less-severe COVID-19 groups. Based on Egger’s test, publication bias was evident in comparison of SARS-CoV-2–positive with –negative subjects ($P = 0.002$) and the funnel plot was asymmetric (Supplemental Figure 4A). The probable reason for publication bias may be that the studies with 25(OH)D data collected before SARS-CoV-2 testing had larger sample sizes and detected smaller differences compared with the studies that measured 25(OH)D after SARS-CoV-2 testing. There was no publication bias in the comparison of severe and less-severe COVID-19 patients ($P = 0.60$); however, a small deviation towards an WMD ∼ −5 and an SE ≈2 was observed in a funnel plot (Supplemental Figure 4B); this implies that studies with a smaller SE (more precision) indicate less difference in 25(OH)D concentration compared with the pooled 25(OH)D concentration. Therefore, it should be considered that a small overestimation is probable. The quality of most of the studies was classified as poor (Supplemental Tables 11–14). Moreover, the strength and limitations of studies are summarized in Supplemental Table 15.
FIGURE 4 Relation between vitamin D deficiency and risk of mortality from COVID-19 in studies that adjusted for confounders (adjusted HR) (A) and studies that did not adjust for confounders (crude OR) (B). COVID-19, coronavirus disease 2019; ES, effect size; MLR, multiple logistic regression.

Discussion

In this systematic review, we investigated the relation between 25(OH)D concentrations and risk of SARS-CoV-2 infection and COVID-19 severity. For this purpose, we systematically reviewed and, where appropriate, meta-analyzed the related retrospective, cohort, cross-sectional, and clinical trial studies that assessed the association of 25(OH)D concentrations and the risk of SARS-CoV-2 infection, composite severity, or 1 feature of severity.

Higher risk of SARS-CoV-2 infection was observed in VDD serum concentrations of 25(OH)D were lower in COVID-19 patients compared with healthy counterparts, as indicated by pooled results of both adjusted and nonadjusted studies. Among the 3 adjusted studies, 2 measured 25(OH)D in the preceding year before SARS-CoV-2 infection (39, 40); the sample sizes in one of these studies were sufficiently powered (case/control: 782/7025) (39). The nonadjusted studies measured 25(OH)D at admission and the sample sizes were sufficient in 4 studies (186/2700, 197/197, 128/219, 335/560) (39, 43, 39, 39). Moreover, concentrations of 25(OH)D were lower in COVID-19 patients compared with healthy subjects. Based on the findings, VDD is associated with increased risk of SARS-CoV-2 infection; however, caution should be made in interpreting these results, since the studies have inherent limitations.

All of the studies indicated a lower concentration of 25(OH)D with more severe status (composite severity) of disease. Furthermore, VDD was associated with composite severity in studies that were both adjusted and not adjusted for confounders. The significant relation between VDD and composite severity was evident in all of the primary studies, except for the Hernández et al. (44) and De Smet et al. (42) studies, where De Smet et al. revealed such a relation only in males but not in females. Zero heterogeneity was estimated for adjusted studies based on the I^2 statistic. It should be noted that the heterogeneity I^2 statistic can be biased in small meta-analyses and so an I^2 of 0.0% does not necessarily reflect perfect homogeneity (67).

Pooled results from the studies that were unadjusted and adjusted studies using Cox survival analysis indicated a higher risk of mortality in VDD; however, the adjusted studies that used logistic regression failed to find a significant relation. The Cox model estimates the instantaneous probability of death at a particular time, while logistic regression estimates the cumulative probability; instantaneous risk could be important as the cumulative probability can be conditioned by a complex clinical outcome. Moreover, it is noteworthy to mention that the Cox model tends to have greater statistical power to detect a significant exposure effect than logistic regression (68). Among the 4 adjusted studies that used logistic regression, 1 study indicated higher risk of mortality in VDD, 2 revealed no significant relation, and 1 study unexpectedly found a lower risk of mortality in VDD. In this study, the prevalence of ≥2 comorbidities was higher in the non-VDD (46.7%) versus the VDD group (30.3%). Although this difference between groups was not statistically significant, it could be important because of the small sample size (n = 30 in non-VDD and n = 99 in VDD). The authors adjusted for some confounders (age, sex, CRP, ischemic heart disease, and severe pneumonia), but the effects of other chronic diseases that were more prevalent in the non-VDD versus VDD groups (albeit nonsignificant) were not adjusted. Moreover, the population in this study was old (mean age of 77 y) and so at high risk for other nutrient deficiencies. The 2 studies that were not included in the analysis also indicated a significant relation, in which 1 study was an RCT (36, 64). Consistently, pooled results indicated a higher concentration of 25(OH)D in patients who survived versus those who died. Overall, evidence indicates that VDD greatly increases the risk of mortality.

Pooled analysis of unadjusted studies failed to detect any significant relation between 25(OH)D concentration and
ICU admission, although an RCT indicated a significant association (36).

For pulmonary complications, results of studies were inconsistent; 4 studies found a significant relation between 25(OH)D concentration and an increased risk of pulmonary involvement, while 4 studies failed to find any relation. Among them, only Radujkovic et al. (13) and Abrishimi et al. (60) were adjusted for confounders, and both found a significant association between VDD and risk of pulmonary involvement. Radujkovic et al. had some other strengths, such as a cohort design and larger sample size, as compared with the other studies. Although this study indicated a very large risk in VDD, the HR in this study was for the combination of both ventilator requirement and death. In Abrishami et al., increases in 25(OH)D concentration led to only a 4% reduction in severe lung involvement. Therefore, it seems pragmatic to suggest that no conclusion can be drawn regarding the relation between 25(OH)D and pulmonary complications.

All 3 studies that examined the association between VDD and hospitalization indicated a significant relation (13, 40, 57). One study adjusted for confounders and had a good quality design (13); another study adjusted for confounders and had a large sample size but the authors used vitamin D data that were measured in the past (40), while the third study did not adjust for confounders and had a poor design (57). With regard to the relation between 25(OH)D concentration and hospital length of stay, 1 study found a significant relation (44), while the other failed to find any relation (46). In total, the evidence is not adequate to draw a conclusion with regard to the association of vitamin D with hospitalization admission and length of stay.

We assessed CRP, D-dimer, ferritin, and IL-6 as the inflammatory markers. Five studies indicated a positive association between 25(OH)D concentration and inflammation. In 2 studies peak CRP and CRP >40 mg/L were evaluated in related to VDD (38, 47). In 1 study, only IL-6 was measured, and in the other 2 studies, the relation was examined using Pearson correlation coefficients (50, 54). Four studies failed to detect a significant relation (14, 44, 64, 61); among them, the highest-quality study was a clinical trial that failed to discern the effect of cholecalciferol supplementation on CRP and D-dimer (14), although it does not appear that 25(OH)D concentration is correlated with inflammation in nonacute phases, given that the evidence is currently not sufficient.

Several mechanisms are involved in elucidating the relation between VDD and SARS-CoV-2 infection risk and outcomes. Vitamin D improves cellular immunity and can decrease the plasma concentrations of proinflammatory cytokines, such as TNF-α and IFN-γ, that have been produced as part of the cytokine storm by the innate immune system in viral infections such as COVID-19, in addition to increasing concentrations of anti-inflammatory markers (69). Furthermore, vitamin D can regulate adaptive immune response by stopping the T-helper (Th) cell type 1 (Th1) reaction, elevating production of cytokine by Th2, and increasing the induction of T-regulatory cells (70–72).

In addition, due to the highly expressed concentrations of vitamin D receptors (VDRs) in B- and T-lymphocytes (73), vitamin D can affect immune system function. VDR is a member of the nuclear hormone receptor (NHR) family, which is a known transcription factor (74); indeed, VDR is present in both T and B immune cells and regulates a variety of metabolic pathways, such as those involved in the immune response and cancer (75). High concentrations of transforming growth factor β (TGF-β) have been reported in the acute phase of COVID-19, where TGF-β signaling is closely related to SARS-CoV-2 and is suppressed by VDR via genomic competition with Mothers against decapentaplegic homolog 3 (Smad3) occupancy on proinflammatory (e.g., IL-6) genes and therefore creating a stable physiologic situation (76).

Another probable mechanism is that vitamin D can induce cathelicidin, IL-37, and defensins as antimicrobial peptides, and promote cellular innate immunity and reduce virus replication (77–79).

It has been posited that vitamin D can enhance the expression of some genes related to antioxidant systems, such as the glutathione reductase gene (80); accordingly, some studies have reported that vitamin D metabolites have vascular-related functions including anticoagulant effects through modifying the expression of thrombomodulin and tissue factor in monocyte and aortic cells (81, 82).

Because of the worldwide increasing prevalence of COVID-19 as a novel pandemic, it is important to research potential antiviral treatments or preventions. Therefore, we conducted this systematic review to investigate the association of vitamin D concentration with SARS-CoV-2 infection and various clinical outcomes.

Some systematic reviews have investigated the association between vitamin D3 and COVID-19 risk and severity (83, 84), in addition to a meta-analysis by Pereira et al. (85), which included 27 studies. The priority of the present study was to include a higher number of studies and exclude preprint articles that had not been peer reviewed and studies with high risk of bias. Moreover, problematically, studies that did and did not adjust for confounding variables were pooled together in the Pereira et al. study, while we analyzed these studies separately.

The main limitation of the present systematic review is the inclusion of studies that were heterogeneous in design, methodology, and statistical approach, and since most of the studies were observational, causality cannot be inferred. Sex and age are important factors that have been shown to be related to both COVID-19 and 25(OH)D concentrations independently. Thus, it is of high importance that the relation between COVID-19 and vitamin D be verified in different subgroups of age and sex. Indeed, we were unable to do so due to the results not being reported separately in the included studies.

In conclusion, although studies were heterogeneous in methodological and statistical approach, and some inherent
limitations were present, the findings of the present study indicated a significant relation between 25(OH)D concentration and SARS-CoV-2 infection, COVID-19 composite severity, and mortality. For infection, caution should be taken in interpreting the results due to inherent limitations of studies. For ICU admission, inflammation, hospitalization, and pulmonary involvement, the evidence is currently inconsistent and insufficient. Moreover, future studies should investigate the association of COVID-19 with vitamin D in subgroups of age and sex.

Acknowledgments

The authors’ responsibilities were as follows—AK: designed the study; AK, VM, and SKA: performed the literature search and screening and wrote the initial draft, which was modified after feedback from all coauthors; AK, VM, and SKA: performed data extraction; MG and AK: performed quality assessment; CCTC and SB: critical revising of the manuscript; AK: had primary responsibility for content; and all authors: read and approved the final manuscript.

References

1. Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 2017;18(2):153–65.
2. Chalmers JD, McHugh BJ, Docherty C, Govan JR, Hill AT. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013;68(1):39–47.
3. Mamani M, Miceli N, Basir HRG, Vasheghani M, PoorojaI J. Association between serum concentration of 25-hydroxyvitamin D and community-acquired pneumonia: a case-control study. Int J Gen Med 2017;10:423.
4. Dancer RC, Parekh D, Lax S, D’Souza V, Zheng S, Bassford CR, Park D, Bartis D, Mahida R, Turner A. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax 2015;70(7):617–24.
5. DeLaca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(6):1689S–96S.
6. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano L, ElKettani ElHamidi C, Nsiri A, AlHarrar R, et al. Nutritional status, functional assessment and disease severity in bronchiectasis. Thorax 2015;70(7):617–24.
7. Zhang R, Naughton DP. Vitamin D in health and disease: current perspectives. Nutrients 2010;2(9):65.
8. Al-Zohily B, Al-Menhali A, Gariballa S, Haq A, Shah I. Epimers of vitamin D: a review. Int J Mol Sci 2020;21(2):470.
9. Al-Hashimi N, Abraham S. Cholecalciferol. StatPearls [Internet] 2020;Treasure Island (FL): StatPearls Publishing. [Accessed 2020 Dec 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549768/.
10. Vieth R. Vitamin D supplementation: cholecalciferol, calcifediol, and calcitriol. Eur J Clin Nutr 2020;74(11):1493–7.
11. World Health Organization. WHO Director-General’s remarks at the media briefing on 19-nCoV on 11 February 2020. Geneva (Switzerland): World Health Organization [Internet]. [Accessed Oct 2020]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.
12. World Health Organization [Internet]. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. [Accessed Feb 2021]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
13. Radujkovic A, Hippchen T, Tiwari-Heckler S, Drehner S, Boxberger M, Merle U. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients 2020;12(9):2757.
14. Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, Puri GD, Malhotra P. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgrad Med J 2020;1:4–4.
15. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.
16. Yamshchikov A, Desai N, Blumberg H, Ziegler T, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009;15(5):438–49.
17. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Gamnna D, Ginde AA. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583.
18. Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Gamnna D, Ginde AA, Goodall EC. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health Technol Assess 2019;23(2):1–44.
19. Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of Covid-19?: Br Med J 2020;369:m1548.
20. Mouradjian MT, Plazak ME, Gale SE, Noel ZR, Watson K, Devabhaktuni S. Pharmacologic management of gout in patients with cardiovascular disease and heart failure. Am J Cardiovasc Drugs 2020;20(5):431–45.
21. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol 2020;16(7):341–2.
22. Roth D, Abrams S, Aloia J, Bergeron G, Bourassa M, Brown K, Calvo M, Cashman K, Combs G, De-Regul L. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. Ann NY Acad Sci 2018;1430(1):44.
23. Wimalawansa SJ. Global epidemic of coronavirus—Covid-19: what can we do to minimize risks? Eur J Biomed 2020;7(3):432–8.
24. Kaufman HW, Niles JK, Kroll MH, BI CX, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PloS One 2020;15 (9):e0239252.
25. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 2020;32(7):1195–8.
26. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Int J Surg 2010;8(5):336–41.
27. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Hospital Research Institute; 2000.[Accessed 2020 Dec 7]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
28. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne J. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
29. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(709):629–34.
30. Rothan D, Byrareddy SN. The epidemiology and pathogenesis of Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. [Accessed Feb 2021]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
31. Radujkovic A, Hippchen T, Tiwari-Heckler S, Drehner S, Boxberger M, Merle U. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients 2020;12(9):2757.
32. Gonçalves TJM, Gonçalves S, Guarnieri A, Risegato RC, Guimarães MP, de Freitas DC, Razuk-Filho A, Benedetto Junior BP, Parrillo EF. Prevalence of obesity and hypovitaminosis D in elderly with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Nutr ESPEN 2020;40:110–4.
33. Haraj NE, El Azir S, Chadli A, Dafr A, Mjaabber A, Aissaoui O, Barrou I, El Kettani El Hamidi C, Nsiri A, Al Harrar R, et al. Nutritional status
assessment in patients with Covid-19 after discharge from the intensive care unit. Clin Nutr ESPEN 2020;20:4123–8.
34. Sun JK, Zhang WH, Zou L, Liu Y, Li JJ, Kan XH, Dai L, Shi QK, Yuan ST, Yu WK, et al. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging 2020;12(12):11287–95.
35. Yilmaz K, Sen V. Is vitamin D deficiency a risk factor for COVID-19 in children? Pediatri Pulmonol 2020;55(2):3595–601.
36. Entrenas Castillo M, Costa LME, Barrios JMV, Diaz JFA, Miranda JL, Bouillon R, Gomez JMQ. Effect of calcitriol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol 2020;203:105762.
37. Blanch-Rubió J, Soldevila-Domenech N, Tío L, Llorente-Onaindía J, Ciria-Recasens M, Polino L, Gurt A, de la Torre R, Maldonado R, Monfort J, et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging 2020;12(20):19923–37.
38. Maghbooli Z, Sahraian MA, Ebrahimi M, Pakozi M, Kafan S, Tabriz HM, Hadadi A, Montazeri M, Nasiri M, Shirvani A, et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for clinical adverse outcomes in patients with COVID-19 infection. PLoS One 2020;15(9):e0239799.
39. Meltzer DO, Best TJ, Zhang H, Yokes T, Arora V, Solway J. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw Open 2020;3(9):e2019722.
40. Merzon E, Tworowski D, Gorohovski A, Vinker S, Cohen AG, Green I, Frenkel-Morgenstern M. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J 2020;287(17):3693–702.
41. Ye K, Tang F, Liao X, Sha W, Deng MQ, Huang GY, Qin ZQ, Peng XM, Xiao HW, Chen GX, et al. Does serum vitamin D level affect COVID-19 infection and its severity? A case-control study. J Am Coll Nutr 2020;1–8.
42. Desert D, De Smet K, Herroelen P, Gryspeerdt S, Martens GA. Serum 25(OH) vitamin D levels in patients hospitalized with SARS-CoV-2 infection. J Clin Endocrinol Metab 2020;203:105751.
43. Ferrari D, Locatelli M. No significant association between vitamin D and COVID-19: a retrospective study from a northern Italian hospital. J Clin Endocrinol Metab 2020;203:105762.
44. Hernández JL, Nan D, Fernandez-Ayala M, García-Unzueta M, Pérez RAR, Puente Nieto AV, Martínez-Cuazitl A, Montelongo M, Cereda E, Bogliolo L, Klersy C, Lobascio F, Masi S, Crotti S, De Carolis C, De Cialini A, Di Sabatino A, et al. Vitamin D deficiency on COVID-19—a prospective analysis from the CovILD Registry. Nutrients 2020;12(9):2775.
45. Macaya F, Espejo C, Palencia C, Fernández-Ortiz A, González Del Castillo J, Martín-Sánchez FJ, Runkle I, Rubio MA. Interaction between age and vitamin D deficiency in severe Covid-19 infection. Nutr Hosp 2020;37(5):1039–42.
46. Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep 2020;10(1):20191.
47. Karahan S, Katkat F. Impact of serum 25(OH) vitamin D level on mortality in patients with COVID-19 in Turkey. J Nutr Health Aging 2021;25:189–96.
48. Karonova TL, Andreeva AT, Vashukova MA. Serum 25(OH)D level in patients with Covid-19. Jurnal Infektologi 2020;12(3):21–7.
49. Annweiler C, Hanotte B, Grandin de l’Eprevre C, Sabatier JM, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients: a quasi-experimental study. J Steroid Biochem Mol Biol 2020;204:105771.
50. Bagheri M, Haghollahi F, Shariat M, Jafarabadi M, Aryanloo P, Rezayof EJ. Supplement usage pattern in a group of COVID-19 patients in Tehran. Journal of Family and Reproductive Health 2020;14(3):158–65.
51. Hamza A, Ahmed M, Ahmed K, Durrani AR. Role of vitamin D in pathogenesis and severity of coronavirus disease 2019 (COVID-19) infection. Pakistan J Med Health Sci 2020;14(2):462–5.
52. Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, Boot CS, Stock N, Macfarlane J, Martineau AR, et al. Low serum 25-hydroxyvitamin D (25(OH)D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. Clin Endocrinol (Oxf) 2020;93(4):508–11.
53. Abrishami A, Dalili N, Mohammad Torbat P, Asgari R, Arab-Ahmadi M, Behnam B, Sanei-Tahter M. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study. Eur J Nutr 2020;1–9.
54. Pizziini A, Aichner M, Sahanic S, Böhm A, Egger A, Hoermann G, Kurz K, Widmann G, Bellmann-Weiler R, Weiss G, et al. Impact of vitamin D deficiency on COVID-19—a prospective analysis from the CovILD Registry. Nutrients 2020;12(9):2775.
55. Anjum S, Suleman A, Afridi S, Yasmeen G, Ikram Shah M, Afridi S. Examine the association between severe vitamin D deficiency and mortality in patients with Covid-19. Pakistan J Med Health Sci 2020;14(3):1184–6.
56. Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically ill COVID-19 patients of a North American community hospital intensive care unit in May 2020: a pilot study. Med Drug Discov 2020;8:100064.
57. Carpagano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, Palumbo A, Di Gioia G, Valerio VN, Resta O. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J Endocrinol Invest 2020;1–7.
58. Cereda E, Bogliolo L, Klersy C, Lobascio F, Masi S, Cotti S, De Stefano L, Bruno R, Corsico AG, Di Sabatino A, et al. Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital. Clin Nutr 2020;50261:5614(20)30601-4.
59. Pérez RAR, Puente Nieto AV, Martínez-Cuaizitl A, Montelongo Mercado EA, Tort AdSM. Deficiency of vitamin D is a risk factor of mortality in patients with COVID-19. 2020;74(1–2):106–13.
60. von Hippel PT. The heterogeneity statistic I(2) can be biased in small trials. Nucl Cardiol 2014;21(4):686–94.
61. Sharihi A, Vahedi H, Nazari R, Sayafi H, Hosseinizadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines activity in vitro. J Immunol 2020;143(5):3032–5.
71. Cantorna MT, Snyder L, Lin Y-D, Yang L. Vitamin D and 1,25 (OH) 2D regulation of T cells. Nutrients 2015;7(4):3011–21.
72. Jeffery LE, Burke P, Mura M, Zheng Y, Qureshi OS, Hewison M, Walker IS, Lammas DA, Raza K, Sansom DM. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009;183(9):5458–67.
73. Gruber-Bzura BM. Vitamin D and influenza—prevention or therapy? Int J Mol Sci 2018;19(8):2419.
74. Evans RM, Lippman SM. Shining light on the COVID-19 pandemic: a vitamin D receptor checkpoint in defense of unregulated wound healing. Cell Metab 2020;32(5):704–9.
75. Adorini L, Daniel KC, Penna G. Vitamin D receptor agonists, cancer and the immune system: an intricate relationship. Curr Top Med Chem 2006;6(12):1297–301.
76. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Labblanc M, Coulter S, He M, Scott C, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013;153 (3):601–13.
77. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauer J, Wu K, Meinken C. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311(5768):1770–3.
78. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, Borregaard N, Modlin RL, Hewison M. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J Immunol 2009;182(7):4289–95.
79. Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, Davidson DJ, Donis RO. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 2011;6(10):e25333.
80. Lei G-S, Zhang C, Cheng B-H, Lee C-H. Mechanisms of action of vitamin D as supplemental therapy for Pneumocystis pneumonia. Antimicrob Agents Chemother 2017;61(10):e01226–17.
81. Ruth Wu-Wong J. Are vitamin D receptor activators useful for the treatment of thrombosis? Curr Opin Investig Drugs 2009;10(9):919.
82. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger P. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006;186(1):20–8.
83. Munshi R, Hussein MH, Toraih EA, Elshazli RM, Jardak C, Sultana N, Youssef MR, Omar M, Attia AS, Fawzy MS, et al. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J Med Virol 2021;93(2):733–40.
84. Mercola J, Grant WB, Wagner C. Evidence regarding vitamin D and risk of COVID-19 and its severity. Nutrients 2020;12(11):3361.
85. Pereira M, Dantas Damascena A, Galvão Azevedo LM, de Almeida Oliveira T, da Mota Santana J. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. Crit Rev Food Sci Nutr 2020;1–9.